| Literature DB >> 33672863 |
Álvaro López-Janeiro1, Ignacio Ruz-Caracuel1, Jorge L Ramón-Patino2, Vivian De Los Ríos3, María Villalba Esparza4,5, Alberto Berjón1,6, Laura Yébenes1,6, Alicia Hernández7,8, Ivan Masetto9, Ece Kadioglu10, Virginie Goubert9, Victoria Heredia-Soto5,11, Rodrigo Barderas12, José Ignacio Casal13, Carlos E de Andrea4, Andrés Redondo2,8,11, Marta Mendiola5,6, Alberto Peláez-García6, David Hardisson1,5,6,8.
Abstract
Low-grade, early-stage endometrial carcinoma (EC) is the most frequent malignant tumor of the uterine corpus. However, the molecular alterations that underlie these tumors are far from being fully understood. The purpose of this study is to describe dysregulated molecular pathways from EC patients. Sixteen samples of tumor tissue and paired healthy controls were collected and both were subjected to mass spectrometry (MS)/MS proteomic analysis. Gene ontology and pathway analysis was performed to discover dysregulated pathways and/or proteins using different databases and bioinformatic tools. Dysregulated pathways were cross-validated in an independent external cohort. Cell signaling, immune response, and cell death-associated pathways were robustly identified. The SLIT/ROBO signaling pathway demonstrated dysregulation at the proteomic and transcriptomic level. Necroptosis and ferroptosis were cell death-associated processes aberrantly regulated, in addition to apoptosis. Immune response-associated pathways showed a dominance of innate immune responses. Tumor immune infiltrates measured by immunofluorescence demonstrated diverse lymphoid and myeloid populations. Our results suggest a role of SLIT/ROBO, necroptosis, and ferroptosis, as well as a prominent role of innate immune response in low-grade, early-stage EC. These results could guide future research in this group of tumors.Entities:
Keywords: SLIT/ROBO; endometrial cancer; ferroptosis; immune microenvironment; low grade; necroptosis; pathways; proteomics
Year: 2021 PMID: 33672863 DOI: 10.3390/cancers13040794
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639